Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 29, 2000

View Archived Issues

Innovata and Vectura to develop inhaled protein and peptide drugs

FDA approves Visicol

Targeted Genetics completes acquisition of Genovo; initiates project with Biogen

New prostate cancer vaccine selected for clinical trials by Progenics, Cytogen

Variagenics and Boehringer Ingelheim join forces for pharmacogenomics program

Autoantibodies found to be associated with autoimmune autonomic neuropathy

Italian researchers report new classes of highly potent nootropic agents

Potential antiatherosclerotic agents presented in Bologna by Latvian investigators

Results of marimastat/carboplatin combination trial in ovarian cancer disappointing

New inhibitors of IMP-1 metallo-beta-lactamase tested in combination with imipenem

Two-antigen combination melanoma vaccine enters phase I/II at MGH

Theratechnologies enhances therapeutic peptide pipeline through acquisition

BioTransplant and Novartis create xenotransplantation research company

Corixa to file Melacine BLA for stage II melanoma

Cytokine grants CNI-1493 license to Axxima

Novasite awarded Phase I SBIR grant for lead molecule identification

O-Vax ovarian cancer vaccine awarded orphan drug status in U.S.

Ampligen clears first stage of regulatory review in the E.U.

AstraZeneca synthesizes new selective opioid agonist analgesics

Fujisawa discontinues development of FK-888

Sagami receives patent for apoptosis inhibitor

3-D researchers patent alphav integrin inhibitors with broad indications

Novel vitronectin receptor antagonists and their use in bone disorders patented

Sanofi-Synthelabo presents new selective NK1 receptor antagonists

University of Virginia researchers patent felbamate derivatives useful for neurological diseases

Neurological compounds disclosed by Cephalon in patent literature

New MMP inhibitors useful for multiple sclerosis, etc.

Eisai receives patent for new compounds interacting with AMPA receptors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...